ACE2 News and Research

RSS

Role of SARS-CoV-2 S1 subunit in severe COVID-19

A new study aimed to determine whether portions of the SARS-CoV-2 spike protein are capable of activating innate immune cells like Gal-3.

30 Mar 2022

Chemical in leafy greens could prevent infections by coronaviruses including SARS-CoV-2

Researchers discuss the use of the isothiocyanate sulforaphane for the treatment of both SARS-CoV-2 and HCoV-OC43 infections.

30 Mar 2022

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Researchers demonstrated the inhalation of an ACE2 decoy receptor, sACE22.v2.4-IgG1, increases survival and ameliorates lung injury in K18-hACE2 transgenic mice.

30 Mar 2022

Researchers create method to track SARS-CoV-2 RBD binding in vivo

Researchers developed a method for tracking the binding of the receptor-binding domain of SARS-CoV-2 in vivo using genetically engineered extracellular vesicles that can migrate to ACE2 expressing cells.

30 Mar 2022

Study analyzed several naturally-occurring amino acid variations found in the extended loop harboring the SARS-CoV-2 S1/S2 cleavage site

A recent study analyzed the polymorphisms in the SARS-CoV-2 spike proteins' S1/S2 subunits.

30 Mar 2022

A ferritin nanoparticle candidate vaccine for COVID

In a recent study published on the bioRxiv* preprint server, the immunogenicity, and effectiveness of SARS-CoV-2 spike ferritin nanoparticle (SpFN) adjuvanted with aluminum hydroxide (AlOH3) or Army Liposomal Formulation QS-21 (ALFQ) in a cynomolgus macaque (CM) COVID-19 model was evaluated.

30 Mar 2022

SARS-CoV-2 nucleocapsid protein linked to COVID-19 severity

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes respiratory coronavirus disease 2019 (COVID-19) triggered an unprecedented public health emergency. Human mobility patterns were fundamental to the spread of SARS-CoV-2 globally. The situation is particularly acute in a country like Saudi Arabia, which has seen more than 750,000 cases and over 9,000 deaths as of March 30th, 2022.

29 Mar 2022

Furin inhibitors as potential therapies to combat SARS-CoV-2 and other diseases

Furin inhibitors as potential therapeutics for treating COVID-19 and other diseases, wherein furin is integral for their pathogenicity and progression.

29 Mar 2022

The different actions of CBD in SARS-CoV-2 infection

An article has described the role of cannabidiol as a potential inhibitor of hyperinflammation in SARS-CoV-2 infection.

29 Mar 2022

Study investigates SARS-CoV-2 infection in Swiss stray cats

Recently, researchers surveyed the prevalence of SARS-CoV-2 infection in Swiss stray cats.

29 Mar 2022

Northwestern scientists continue to advance the understanding of COVID-19

As the COVID-19 pandemic enters its third year, Northwestern Medicine scientists continue to help advance the understanding of the disease and its impact, from investigating antibody protection against COVID-19 reinfection to elevating women in academic research and highlighting racial and ethnic disparities in COVID-19 hospital mortality in Illinois.

28 Mar 2022

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Researchers evaluated the ability of RBD antibodies to bind to and neutralize SARS-CoV-2 Omicron variant.

28 Mar 2022

Tuberculosis infection protects mice against COVID-19

To study if prior Mtb infection affects the response to CoV2 infection, K18-hACE2 (ACE2) and C57BL/6 (B6) mice were infected with Mtb, and post thirty days, were exposed to CoV2.

27 Mar 2022

Study finds methylene blue is a low-micromolar inhibitor of the the SARS-CoV-2 spike protein and ACE2 interaction

A new study has focussed on screening and identification of possible SMIs of this PPI for COVID-19.

25 Mar 2022

Study explores macrophage susceptibility to SARS-CoV-2 virions

A new study investigated the susceptibility of macrophages to SARS-CoV-2 virions.

25 Mar 2022

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A recent study presented topologically engineered fragment crystallizable-fusion proteins and antibodies as therapeutic options for diseases like human coronaviruses infections and cancers.

25 Mar 2022

Study evaluates the clinical accuracy of two FDA-approved rapid antigen tests across SARS-CoV-2 variants

Researchers evaluated clinical accuracy and analytical detection capabilities of the two US Food and Drug Administration-approved rapid antigen tests across SARS-CoV-2 variants.

25 Mar 2022

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

Researchers used a CNN regression model to investigate the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex.

25 Mar 2022

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

A team of international scientists has developed an mRNA-based coronavirus disease 2019 (COVID-19) vaccine encoding the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant. The vaccine candidate has shown high efficacy in inducing neutralizing antibodies and protecting against delta infection in mice. The study is currently available on the bioRxiv* preprint server.

24 Mar 2022

Breast milk components show potent in vitro SARS-CoV-2 inhibition

Human breastmilk contains substances that can inhibit infection by SARS-CoV-2 and its variants, as well as prevent its replication.

24 Mar 2022

ACE2 News and Research

Role of SARS-CoV-2 S1 subunit in severe COVID-19

Chemical in leafy greens could prevent infections by coronaviruses including SARS-CoV-2

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Researchers create method to track SARS-CoV-2 RBD binding in vivo

Study analyzed several naturally-occurring amino acid variations found in the extended loop harboring the SARS-CoV-2 S1/S2 cleavage site

A ferritin nanoparticle candidate vaccine for COVID

SARS-CoV-2 nucleocapsid protein linked to COVID-19 severity

Furin inhibitors as potential therapies to combat SARS-CoV-2 and other diseases

The different actions of CBD in SARS-CoV-2 infection

Study investigates SARS-CoV-2 infection in Swiss stray cats

Northwestern scientists continue to advance the understanding of COVID-19

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Tuberculosis infection protects mice against COVID-19

Study finds methylene blue is a low-micromolar inhibitor of the the SARS-CoV-2 spike protein and ACE2 interaction

Study explores macrophage susceptibility to SARS-CoV-2 virions

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

Study evaluates the clinical accuracy of two FDA-approved rapid antigen tests across SARS-CoV-2 variants

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

A novel mRNA vaccine encoding delta RBD induces high neutralizing antibody titers

Breast milk components show potent in vitro SARS-CoV-2 inhibition

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News